ProtoKinetix is a research and development stage biotechnology company focused on the development of a single molecule, AAGP (Anti-Freeze Glycoprotein). The company investigates potential medical and commercial applications for AAGP, with an emphasis on healthcare solutions. A key area of active research involves using AAGP in the treatment of Type 1 Diabetes, including work on islet-like cells derived from patient stem cells. ProtoKinetix has no commercialized products and generates no revenue. The company's business model relies on raising capital to fund its research and development activities. ProtoKinetix operates by sponsoring external scientific research and collaborating with independent researchers and advisors to advance the molecule toward commercialization. The company's path to revenue and long-term commercial viability depends entirely on successfully developing and commercializing AAGP.